MOSHE TALPAZ, M.D.; GIORA MAVLIGIT, M.D.; MICHAEL KEATING, M.D.; RONALD S. WALTERS, M.D.; JORDAN U. GUTTERMAN, M.D.
Nine patients with refractory chronic myelogenous leukemia and severe symptomatic thrombocytosis (≥ 1 x 106 platelets/mm3) were given partially purified human leukocyte interferon-alpha. A significant decline in platelet counts, from a mean (> SE) of 1.71 ± 0.53 x 106/mm3 to a mean of 0.52 ± 0.24 x 106/mm3 (p < 0.01), resulted in all patients. Maintenance of low platelet counts was achieved in two patients for more than 143 and 300 days, respectively. Treatment with human leukocyte interferon-alpha was stopped in the remaining patients because of increases in the leukocyte count, toxicity, or both. Our preliminary observations suggest that human leukocyte interferon-alpha may significantly alleviate progressive thrombocytosis in advanced chronic myelogenous leukemia. Further studies of human leukocyte interferon-alpha and chemotherapeutic agents are indicated.
TALPAZ M, MAVLIGIT G, KEATING M, WALTERS RS, GUTTERMAN JU. Human Leukocyte Interferon to Control Thrombocytosis in Chronic Myelogenous Leukemia. Ann Intern Med. ;99:789–792. doi: 10.7326/0003-4819-99-6-789
Download citation file:
Published: Ann Intern Med. 1983;99(6):789-792.
Hematology/Oncology, Leukemia/Lymphoma, Platelet Disorders.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use